Avivagen Exhibits at Winter Woofstock

OTTAWA, ONTARIO, December 6, 2012 - Avivagen Inc. (TSXV:VIV), a wellness company, exhibited at Winter Woofstock, a canine-centered event, which recently took place at the Direct Energy Centre in downtown Toronto. This annual event attracted over 25,000 pet owners and their dogs.


Jennifer Febel, Marketing and Social Media Associate for Avivagen Animal Health, was on hand informing pet owners about the health benefits of OxC-beta, the active ingredient in Avivagen's canine supplement Oximunol(TM) Chewables, and handing out sample bottles to give owners a chance to experience the results themselves. "The people I spoke with were very interested to learn that Oximunol supports immune health and offers numerous health benefits for their dogs. We also had several pet owners tell us they first learned about our supplement at last year's Winter Woofstock event and let us know just how great their dogs have been doing since first trying the product."


Over 120 dogs and their owners received samples of Oximunol Chewables along with an informative brochure outlining the benefits of this canine supplement. Pet owners were not the only ones stopping by the Avivagen booth. Several veterinarians and veterinary technicians also stopped by to pick up a sample bottle and learn more about the unique canine supplement. Jennifer is following up with these pet owners via email and social media to gather valuable feedback and see how the dogs are doing.


Jennifer opined the event was a great success. "There's such an incredible vibe at Winter Woofstock. Everyone is here for one purpose: to make the lives of their dogs better. Just about every pet-related company you can think of is here and the Woofstock crew has done a wonderful job organizing fun events like a doggy fashion show and even a canine dating area! Overall it was a great event, a big success for Avivagen and a pleasure to attend and be involved."


About OxC-beta and Oximunol(TM) Chewables - "Optimized Health in a Chewable Tablet"


OxC-beta is Avivagen's proprietary, concentrated source of oxidized carotenoid, containing oxidation compounds that occur extensively in the plant world in minute amounts. Results of clinical trials in animals and in vitro studies indicate OxC-beta helps support immune function, which can result in general overall health improvement. Specific benefits include better growth, utilization of feed and decreased mortality in poultry and swine. It is currently available for dogs of all ages in the form of Oximunol(TM) Chewables, which work with a dog's immune system to optimize overall health and well-being


About Avivagen


Avivagen, a wellness company, is developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Avivagen is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.avivagen.com.


Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


For more information:

David Hankinson

CEO, Avivagen Inc.

Phone: 902-825-9270

[email protected]


Graham Burton, PhD

President and Co-Founder, Avivagen Inc.

Phone: 613-990-0969

[email protected]